Viridian Therapeutics

171 articles with Viridian Therapeutics

• Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

  3/8/2023

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022.

• Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

  3/7/2023

  Viridian Therapeutics, Inc. today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida.

• Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 337,000 shares of the Company’s common stock to three new employees on March 1, 2023.

• Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

  3/1/2023

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results.

• Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference

  2/28/2023

  Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that senior management will present at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 1:30 p.m. ET in Boston, MA.

• Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

  2/7/2023

  Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET.

• Viridian Appoints Scott Myers as President and Chief Executive OfficerTransition highlights Viridian’s progression towards becoming a fully-integrated biopharmaceutical company

  2/6/2023

  Viridian Therapeutics, Inc. today announced that the Company has appointed Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today February 6, 2023.

• Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - February 02, 2023

  2/2/2023

  Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the Company’s common stock to four new employees on February 1, 2023.

• Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

  1/8/2023

  Viridian Therapeutics, Inc. announced positive topline clinical data from the third, low dose cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor antibody, in patients with active thyroid eye disease.

• Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2023

  1/5/2023

  Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 35,000 shares of the Company’s common stock on January 3, 2023.

• Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Viridian Therapeutics, Inc. today announced that its President and Chief Executive Officer, Jonathan Violin, Ph.D., will present an overview of the company along with its upcoming corporate priorities at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 2:15 p.m.

• Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease

  12/21/2022

  Viridian Therapeutics, Inc. today announced that the first patient has been enrolled in its THRIVE Phase 3 trial evaluating the efficacy and safety of the investigational agent VRDN-001 in patients with active thyroid eye disease (TED).

• Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 07, 2022

  12/7/2022

  Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 215,000 shares of the Company’s common stock on December 1, 2022.

• Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

  11/28/2022

  Viridian Therapeutics, Inc. today announced that senior management will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.   

• Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

  11/14/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the third quarter ending September 30, 2022 and provided corporate updates.

• Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

  11/14/2022

  Viridian Therapeutics, Inc. today announced positive topline clinical data from the first two cohorts in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED).

• Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

  11/8/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the third quarter ended September 30, 2022, before the financial markets open on Monday, November 14, 2022.

• Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th

  11/8/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that management will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on Tuesday, November 15, 2022.

• Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

  10/22/2022

  Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, presented positive proof-of-concept data from the 10 mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease.

• Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting

  10/12/2022

  Viridian Therapeutics, Inc. today announced that three abstracts highlighting the potential benefits of VRDN-001 will be presented as oral highlighted and late-breaking poster presentations at the 91st Annual Meeting of the American Thyroid Association (ATA), to be held in Montreal, Canada from October 19 to 23, 2022.